Vaginal prasterone

A vaginal formulation of prasterone (DHEA) as 6.5 mg pessaries used in genitourinary syndrome of the menopause. It is metabolised locally into oestrogenic compounds; according to the 2025 AUA/SUFU/AUGS guideline it does not increase the risk of breast cancer, although it has not been studied in women with a history of breast cancer.

Institutional endorsement by Clínica Evolution

This entry is for information. Your case requires an individual medical assessment.